Travaux scientifiques

Doç. Dr. Osman Köstek

197 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Which patients with colorectal cancer develop brain metastases? A multicenter analysis of clinical and molecular predictors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.218 Texte intégral en libre accèsSource : OpenAlex

  2. Clinicopathologic and molecular characteristics of colorectal cancer patients with brain metastases: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-69206-x Texte intégral en libre accèsSource : OpenAlex

  3. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Texte intégral en libre accèsSource : OpenAlex

  5. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

    JCO Global Oncology, 2026

    DOI 10.1200/go-25-00234 PMID 41855443 Texte intégral en libre accèsSource : OpenAlex

  6. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Texte intégral en libre accèsSource : OpenAlex

  7. Predictors of Recurrence Following Curative-Intent Local Therapy for Oligometastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study from the Turkish Oncology Group (TOG)

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612571 Source : ORCID

  8. Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15134901 PMID 42452362 Texte intégral en libre accèsSource : ORCID

  9. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020798 PMID 41598735 Texte intégral en libre accèsSource : ORCID

  10. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020890 PMID 41598826 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  11. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

    Medicina, 2026

    DOI 10.3390/medicina62010098 PMID 41597384 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  12. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062353 PMID 41899277 Texte intégral en libre accèsSource : ORCID

  13. Abstract PS1-11-04: Her2-low expression is associated with inferior progression-free survival in hr-positive metastatic breast cancer treated with CDK4/6 inhibitors

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps1-11-04 Source : OpenAlex

  14. Vascular FDG Uptake on PET/CT in Patients Receiving Immune Checkpoint Inhibitors

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-8-9 Texte intégral en libre accèsSource : OpenAlex

  15. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

    Brain Sciences, 2026

    DOI 10.3390/brainsci16010097 PMID 41594818 Texte intégral en libre accèsSource : ORCID

  16. Drug-specific timing and fatality patterns of EGFR-TKI-associated interstitial lung disease in NSCLC-related JADER reports

    Naunyn-Schmiedeberg's archives of pharmacology, 2026

    DOI 10.1007/s00210-026-05751-6 PMID 42496703 Source : Europe PMC

  17. Circulating Tumor DNA-Based Assessment of Minimal Residual Disease in Colorectal Cancer: Prognostic and Predictive Implications

    Cancers, 2026

    DOI 10.3390/cancers18050754 PMID 41827689 2 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  18. Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score

    BMC cancer, 2026

    DOI 10.1186/s12885-026-16194-w PMID 42174513 Texte intégral en libre accèsSource : Europe PMC

  19. Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature

    Current Medical Research and Opinion, 2026

    DOI 10.1080/03007995.2026.2629092 PMID 41700432 3 citations (OpenAlex) Source : OpenAlex

  20. Acquired CD74–ROS1 fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report

    Journal of Chemotherapy, 2026

    DOI 10.1080/1120009x.2026.2657116 PMID 41992733 2 citations (OpenAlex) Source : OpenAlex

  21. Efficacy and safety of sacituzumab govitecan in hormone receptor–positive metastatic breast cancer: A systematic review and meta-analysis

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261462434 PMID 42317162 2 citations (OpenAlex) Source : OpenAlex

  22. Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence

    Cancer Control, 2026

    DOI 10.1177/10732748261451083 PMID 42104817 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  23. Capecitabine-induced pneumonitis: a rare case report and literature review

    Anti-Cancer Drugs, 2026

    DOI 10.1097/cad.0000000000001839 PMID 42668437 1 citation (OpenAlex) Source : OpenAlex

  24. Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

    BMC Health Services Research, 2026

    DOI 10.1186/s12913-026-15432-y 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  25. 132P Neutrophil–lymphocyte ratio as an independent prognostic marker in chondrosarcoma: A single-center cohort

    ESMO rare cancers., 2026

    DOI 10.1016/j.esmorc.2026.100338 Texte intégral en libre accèsSource : OpenAlex

  26. Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience

    Journal of Gastrointestinal Cancer, 2026

    DOI 10.1007/s12029-026-01457-3 PMID 41944932 Source : OpenAlex

  27. Treatment Adherence and Quality of Life in Hypertensive Cancer Patients Receiving Chemotherapy

    Trends in pharmacy., 2026

    DOI 10.5152/trendspharm.2026.26001 Texte intégral en libre accèsSource : OpenAlex

  28. Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study

    Annals of Saudi Medicine, 2026

    DOI 10.5144/0256-4947.2026.169 PMID 42251515 Texte intégral en libre accèsSource : OpenAlex

  29. Prognostic Significance of Postoperative Edema in Surgically Treated Non-glioblastoma Diffuse Glioma

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-2-2 Texte intégral en libre accèsSource : OpenAlex

  30. 622eP Claudin 18.2 expression in locally advanced and metastatic gastric adenocarcinoma: A single-center retrospective clinicopathological study

    Annals of Oncology, 2026

    DOI 10.1016/j.annonc.2026.05.661 Source : OpenAlex

  31. Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176790 PMID 42739793 Texte intégral en libre accèsSource : OpenAlex

  32. Prognostic Value of a Seven-Factor Risk Stratification System in T3N0 Colon Cancer: A Single-Center Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62101846 PMID 42942377 Texte intégral en libre accèsSource : OpenAlex

  33. Healthy Lifestyle Behaviors and Health Literacy in Oncology Patients: Evaluation of Organic Food Consumption and Physical Activity

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.269303 Source : OpenAlex

  34. Temporal Changes in Age at Diagnosis of Colorectal Cancer in Turkiye: A 9-Year Single-Center Analysis

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612638 Source : OpenAlex

  35. Real-world plasma-based next-generation sequencing findings in metastatic lung adenocarcinoma: a single-center retrospective study

    Marmara medical journal, 2026

    DOI 10.5472/marumj.2070752 Texte intégral en libre accèsSource : OpenAlex

  36. Complete response to fourth-line nivolumab in metastatic hepatocellular carcinoma: A case report

    Marmara medical journal, 2026

    DOI 10.5472/marumj.2071755 Texte intégral en libre accèsSource : OpenAlex

  37. Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative Analysis

    Nigerian Journal of Clinical Practice, 2025

    DOI 10.4103/njcp.njcp_848_23 PMID 40326903 Texte intégral en libre accèsSource : OpenAlex

  38. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-87553-z PMID 39863702 Texte intégral en libre accèsSource : OpenAlex

  39. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2024.2430845 PMID 39588941 1 citation (Europe PMC) Source : ORCID

  40. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

    Turkish Journal of Gastroenterology, 2025

    DOI 10.5152/tjg.2025.24784 PMID 40241388 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  41. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1575691 Texte intégral en libre accèsSource : ORCID

  42. Oncological perspective on Kaposi sarcoma: A single-centre experience

    Marmara Medical Journal, 2025

    DOI 10.5472/marumj.1627569 Texte intégral en libre accèsSource : ORCID

  43. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-18 Texte intégral en libre accèsSource : OpenAlex

  44. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study

    Annals of Saudi Medicine, 2025

    DOI 10.5144/0256-4947.2025.249 PMID 40753462 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  45. Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization

    The Prostate, 2025

    DOI 10.1002/pros.24876 PMID 39972650 8 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  46. Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups

    The Breast Journal, 2025

    DOI 10.1155/tbj/5577345 PMID 40620732 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  47. Assessment of new pathological markers in early stage colon cancer: Insights and limitations

    World Journal of Gastrointestinal Oncology, 2025

    DOI 10.4251/wjgo.v17.i3.101325 PMID 40092924 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  48. Complete response after two cycles of enfortumab vedotin in a patient with metastatic bladder cancer: A case report

    Tumor Discovery, 2025

    DOI 10.36922/td025150026 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  49. Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience

    Nutrition and Cancer, 2025

    DOI 10.1080/01635581.2025.2496371 PMID 40327413 1 citation (OpenAlex) Source : OpenAlex

  50. Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?

    Oncology in Clinical Practice, 2025

    DOI 10.5603/ocp.101970 Texte intégral en libre accèsSource : OpenAlex